RE-BVS – Piemonte Repository

Sfoglia per AUTORE
LONARDI S
Collezione ASL Biella

Items : 14

Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study. in Targeted oncology / Target Oncol. 2024 May;19(3):359-370. doi: 10.1007/s11523-024-01060-1. Epub 2024 May 1.

2024
ASL Biella
AOU Città della Salute di Torino

Aldrighetti L; Ratti F; De Rosa A; Zanuso V; Niger M; Fornaro L; Rossari F; Satolli MA; Garattini SK; Brandi G; Brunetti O; Leone F; Diana A; Pirrone C; Toma I; Pretta A; Landriscina M; Lorenzo A; Gusmaroli E; Bergamo F; Balsano R; Winchler C; Salani F; Formica V; Schirripa M; Aprile G; Garajova I; Martinelli E; Rapposelli IG; et alii...

Survival trends over 20 years in patients with advanced cholangiocarcinoma: Results from a national retrospective analysis of 922 cases in Italy. in Frontiers in oncology / Front Oncol. 2023 Apr 5;13:1128930. doi: 10.3389/fonc.2023.1128930. eCollection 2023.

2023
ASL Biella
AOU Città della Salute di Torino

Lonardi S; Aprile G; Rizzo A; Satolli MA; Aglietta M; Silvestris N; Santini D; Faloppi L; Scartozzi M; Leone F; Brandi G; Fornaro L; Casadei-Gardini A;

Risk-adjusted analysis of survival variability among hospitals treating biliary malignancy. in Journal of chemotherapy (Florence, Italy) / J Chemother. 2022 Dec;34(8):543-549. doi: 10.1080/1120009X.2022.2036557. Epub 2022 Feb 14.

2022
ASL Biella
AO Ordine Mauriziano
AOU Città della Salute di Torino

Cucchetti A; Ratti F; Aldrighetti L; Cascinu S; Burgio V; Faloppi L; Sperti E; Pellino A; Scartozzi M; Satolli MA; Salani F; Fenocchio E; Vivaldi C; Aprile G; Frega G; Aglietta M; Masi G; Filippi R; Galizia E; Palloni A; Santini D; Lonardi S; Lai E; Montagnani F; Pella N; Silvestris N; Fornaro L; Brandi G; Leone F; et alii...

Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial. in ESMO open / ESMO Open. 2020 Sep;5(5):e000911. doi: 10.1136/esmoopen-2020-000911.

2020
ASL Biella

Sartore-Bianchi A; Lonardi S; Martino C; Fenocchio E; Tosi F; Ghezzi S; Leone F; Bergamo F; Zagonel V; Ciardiello F; Ardizzoni A; Amatu A; Bencardino K; Valtorta E; Grassi E; Torri V; Bonoldi E; Sapino A; Vanzulli A; Regge D; Cappello G; Bardelli A; Trusolino L; Marsoni S; Siena S;

Author Correction: Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy. in Scientific reports / Sci Rep. 2020 Jan 31;10(1):1918. doi: 10.1038/s41598-020-58486-6.

2020
ASL Biella

Ruzzo A; Graziano F; Galli F; Galli F; Rulli E; Lonardi S; Ronzoni M; Massidda B; Zagonel V; Pella N; Mucciarini C; Labianca R; Ionta MT; Bagaloni I; Veltri E; Sozzi P; Barni S; Ricci V; Foltran L; Nicolini M; Biondi E; Bramati A; Turci D; Lazzarelli S; Verusio C; Bergamo F; Sobrero A; Frontini L; Magnani M; et alii...

Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer. in Clinical colorectal cancer / Clin Colorectal Cancer. 2020 Dec;19(4):256-262.e2. doi: 10.1016/j.clcc.2020.06.009. Epub 2020 Jun 27

2020
ASL Biella

Tosi F; Sartore-Bianchi A; Lonardi S; Amatu A; Leone F; Ghezzi S; Martino C; Bencardino K; Bonazzina E; Bergamo F; Fenocchio E; Martinelli E; Troiani T; Siravegna G; Mauri G; Torri V; Marrapese G; Valtorta E; Cassingena A; Cappello G; Bonoldi E; Vanzulli A; Regge D; Ciardiello F; Zagonel V; Bardelli A; Trusolino L; Marsoni S; Siena S; et alii...

Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes in Oncologist

2020
ASL Biella

Loupakis F; Depetris I; Biason P; Intini R; Prete AA; Leone F; Lombardi P; Filippi R; Spallanzani A; Cascinu S; Bonetti LR; Maddalena G; Valeri N; Sottoriva A; Zapata L; Salmaso R; Munari G; Rugge M; Dei Tos AP; Golovato J; Sanborn JZ; Nguyen A; Schirripa M; Zagonel V; Lonardi S; Fassan M;

Khorana score and thromboembolic risk in stage II–III colorectal cancer patients: a post hoc analysis from the adjuvant TOSCA trial in Therapeutic Advances in Medical Oncology

2020
ASL Biella

Barni S; Rosati G; Lonardi S; Pella N; Banzi M; Zampino MG; Dotti KF; Rimassa L; Marchetti P; Maiello E; Artioli F; Ferrari D; Labianca R; Bidoli P; Zaniboni A; Sobrero A; Iaffaioli V; De Placido S; Frassineti GL; Ciarlo A; Buonadonna A; Silvestris N; Piazza E; Pavesi L; Moroni M; Clerico M; Aglietta M; Giordani P; Galli F; et alii...

Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy. in Scientific reports / Sci Rep. 2019 Aug 8;9(1):11527. doi: 10.1038/s41598-019-47627-1.

2019
ASL Biella

Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations in European Journal of Cancer

2019
ASL Biella

Neuzillet C; Casadei Gardini A; Brieau B; Vivaldi C; Smolenschi C; Brandi G; Tougeron D; Filippi R; Vienot A; Silvestris N; Pointet A-L; Lonardi S; Rousseau B; Scartozzi M; Dahan L; Aprile G; Boussaha T; Malka D; Crusz SM; Le Sourd S; Meurisse A; Lièvre A; Vernerey D; Evesque L; Heurgué A; Desramé J; Lecomte T; Cacheux W; Bachet J-B; et alii...

Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients. in British journal of cancer / Br J Cancer. 2017 Oct 24;117(9):1269-1277. doi: 10.1038/bjc.2017.289. Epub 2017 Aug 24.

2017
ASL Biella

Germline variants and clinical outcomes of high-risk stage II and stage III colon cancer patients treated with oxaliplatin and fluoropyrimidines adjuvant chemotherapy: A pharmacogenetic ancillary study to TOSCA trial in Annals of Oncology

2017
ASL Biella

Ruzzo A; Galli F; Galli F; Rulli E; Lonardi S; Zagonel V; Ronzoni M; Ionta MT; Pella N; Mucciarini C; Labianca R; Veltri E; Sozzi P; Barni S; Nicolini M; Biondi E; Bramati A; Turci D; Buscaglia M; Magnani M; Graziano F;

First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: Final results of the Italian Research Group for Digestive Tract Cancer (GISCAD) CENTRAL (ColorEctalvastiNTRiAlLdh) and SENTRAL (Serum angiogenesis-cENTRAL) analysis in Journal of Clinical Oncology

2016
ASL Biella

Scartozzi M; Giampieri R; Daniele B; Ferrari D; Lonardi S; Zaniboni A; Cavanna L; Rosati G; Pella N; Zampino MG; Sozzi P; Casula L; Cozzi L; Germano D; Puzzoni M; Loretelli C; Zagonel V; Labianca R; Frontini L; Cascinu S;

Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients. in Scientific reports / Sci Rep. 2014 Nov 5;4:6828. doi: 10.1038/srep06828.

2014
ASL Biella

Ruzzo A; Graziano F; Galli F; Giacomini E; Floriani I; Galli F; Rulli E; Lonardi S; Ronzoni M; Massidda B; Zagonel V; Pella N; Mucciarini C; Labianca R; Ionta MT; Veltri E; Sozzi P; Barni S; Ricci V; Foltran L; Nicolini M; Biondi E; Bramati A; Turci D; Lazzarelli S; Verusio C; Bergamo F; Sobrero A; Frontini L; et alii...